Breathe Well Live Well
ProPublica |
Overuse, Safety Questions Cloud Advair's Ascent to Asthma Blockbuster
ProPublica The asthma drug has generated more than $80 billion in global revenues for its maker, GlaxoSmithKline, since its U.S. approval in 2000. With its distinctive purple inhaler, Advair has helped legions of asthma sufferers achieve control of their symptoms. |
View full post on asthma – Google News
|
Regeneron speeds toward the FDA with its would-be asthma blockbuster
FierceBiotech Meanwhile, after meeting with the FDA, Regeneron now believes the agency will recognize an earlier Phase IIb asthma study as one of two required pivotal trials. In that trial, the highest doses of dupilumab significantly beat out placebo in improving … Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in … |
View full post on asthma – Google News
OpEdNews |
Did you or your children use the blockbuster asthma drug Singulair?
OpEdNews World sales of Merck's asthma drug Singulair were about $5 billion a year until 2012 when its patent expired and it was the U.S.'s seventh best-selling drug. But in September, data from an FDA committee were presented that acknowledge "safety concerns" … |
View full post on asthma – Google News
|
AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster
FierceBiotech Benralizumab–an IL-5 antibody–reduced the rate of asthma exacerbations, hitting the primary endpoint in the trial, says AstraZeneca ($AZN). But the study flagged weak results for the low end of the doses used in the trial, with the top dose doing … AstraZeneca share price: Novel drug shows positive results for severe asthma AstraZeneca's benralizumab succeeds in severe asthma |
View full post on asthma – Google News
Fox News |
FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair
FiercePharma It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis ($NVS) and Roche ($RHHBY). Now the agency is taking action, slapping … FDA says asthma drug Xolair raises risk of heart, brain problems Heart, Mini-Stroke Risks From Asthma Drug: FDA FDA adds cardiovascular risks to Xolair label for asthma treatment |
View full post on asthma – Google News
Reuters UK |
AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown
FierceBiotech Receptos, meanwhile, in-licensed an IL-13 drug from AbbVie after the pharma company decided to de-prioritize its respiratory efforts, including a program for asthma. Receptos is testing RPC4046 for Eosinophilic esophagitis, an orphan disease, and … AstraZeneca starts final-stage tests on severe asthma drug AstraZeneca share price: Drugmaker starts late-stage asthma drug trial AZ severe asthma drug tralokinumab goes into Phase III |
View full post on asthma – Google News
Drug Discovery & Development |
Roche scores upbeat data for a personalized asthma drug with blockbuster hopes
FierceBiotech Roche's ($RHHBY) lebrikizumab significantly reduced the rate of asthma attacks in patients with a severe form of the disease, according to mid-stage trial results, lighting the way for a Phase III study on the novel, personalized treatment. The drug … Biologic May Tame Severe Asthma Roche drug cuts asthma attacks, improves lung function -study Lebrikizumab Phase 2b Data Show Reduction of Asthma Attack Rates |
View full post on asthma – Google News
French Tribune |
Novartis says asthma blockbuster Xolair also effective against serious hives
FiercePharma But Novartis says in financial filings that its pricing is under pressure for the asthma treatment. In the U.K., the price watchdog NICE last fall indicated it might drop approval of the drug there but then relented in March after Novartis offered up … Novartis reports new Phase III data showing omalizumab significantly improves … Novartis skin drug helps patients with chronic hives Novartis' omalizumab effective for severe hives |
View full post on asthma – Google News
|
Dupilumab Could End of Being 'Blockbuster' Asthma Drug – Analyst (SNY) (REGN)
StreetInsider.com (subscription) Dupilumab may debut in 2018 as a treatment for skin and/or asthma conditions, Fernandez said. He observes the large market for asthma, with competition expected from the likes of AstraZenece (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), and others. |
View full post on asthma – Google News
|
Sweden approves copy of GSK asthma blockbuster
FiercePharma Swedish regulators have approved a knock-off version of the asthma drug, which brought in more than $8 billion in 2010 sales for GSK, paving the way for it to be sold in Germany, Italy, Portugal, Hungary and the Czech and Slovak Republics, … Glaxo's Advair Faces Sales Decline on Swedish Generic Approval Glaxo's Advair Faces Sales Decline on Swedish Generic Approval |
View full post on asthma – Google News